BACK

Benj Garrett

Benj Garrett

Partner

New York Office  |  benj.garrett@torreya.com   |   212.257.5807

Benj Garrett, Partner, has been lead banker on well over a billion dollars of transactions while at Torreya, generating substantial amounts of the firm’s total revenue over multiple years. He joined the firm in 2008 and was made the youngest Managing Director.

His experience crosses a wide spectrum in the life sciences, having led transactions as early as preclinical biotech, clinical stage, commercial stage and generics. Over a number of years, he has been successful in both origination and execution roles.

His experience covers cross-border transactions from both Japanese and Indian pharmaceutical companies. Recent notable transactions on which Benj has worked include Santen acquisition of Eyevance, Avenue Therapeutics sale to Cipla, Tris debt recapitalization and the acquisition of NextWave Pharmaceuticals from Pfizer, and Sawai acquisition of the generics business of Upsher-Smith.

Benj graduated summa cum laude from NYU’s Stern School of Business, with a B.S. in finance and statistics.

Selected Transactions

OtiTopic
Acquired by
PMI
August 2021
Santen
Acquisition of
Eyevance
$225 million
September 2020
Avenue Therapeutics
Sale of stock and conditional sale to
Cipla
$215 million + CVRs
February 2019
Tris
Debt recapitalization and acquisition of NextWave Pharmaceuticals from
Pfizer
$125 million
September 2018
Sawai
Acquisition of
generics business of
Upsher-Smith
$1.05 billion
June 2017
HBT Labs
Acquired by
American Regent
August 2022
Mustang
Venture debt raise with
Horizon Technology Finance
$20 million
April 2019
Sandoz
Sale of
Sevelamer ANDA to
TWI Pharmaceuticals
October 2018
Sandoz
Sale of
ANDA portfolio to
CASI Pharmaceuticals
January 2018
Sandoz
Sale of
generics portfolio to
FosunPharma
$18 million
August 2017
XOMA
Sale of royalties to
Healthcare Royalty Partners
$22 million
December 2016
SciDose
Partial sale of royalty
and milestones
Undisclosed
$40 million
September 2016
Academic Investor
Sale of
phase II enzyme replacement royalty
Undisclosed
August 2016
Plexcera Therapeutics
Sale and contribution of orphan disease asset to
Roivant Sciences
May 2016
Eisai
Sale of Akarx to
PBM Capital Group
March 2016
Sandoz
Sale of
Zonalon® to
Renaissance Pharma
March 2015
Flamel Technologies
Sale of Pessac plant to
Recipharm AB
Up to €22 million
November 2014
Sandoz
Divestiture of
certain abbreviated
new drug applications to
IDT Australia
Up to $18 million
October 2014
Concordia International Corp.
Acquisition of
Donnatal® from
Revive Pharmaceuticals
$328 million
May 2014
Teva
Sale of 31 abbreviated
new drug applications to
ANI Pharmaceuticals
$12.5 million +
profit share
December 2013
Pinnacle Biologics
Sale to
Concordia Healthcare
December 2013
Correvio
Sale to
Cardiome
19.9% of shares +
$12 million
November 2013
Shionogi
Sale of Naprelan® to
Alvogen
November 2013
Shionogi
Divestiture of three pediatric drugs to
Concordia Pharmaceuticals
$28.7 million
May 2013
GTx
Sale of Fareston® to
Prostrakan/Kyowa Hakko Kirin
$21.7 million
October 2012
Shionogi
Divestiture of
Cuvposa® to
Merz
August 2012
Quinnova
Sale of dermatology specialty pharma
business to
Amneal
December 2010
Three Rivers Pharma
Sale to
Kadmon
$100+ million
October 2010
GTCR
Advisor in the acquisition of six products from
UCB
July 2010
Columbia Labs
Sale of
Crinone® & Prochieve® product lines and
shares to
Watson
$92.5 million with
$47 million upfront
July 2010
Shareholder Group
Advisor to Genentech
major shareholder
in sale to
Roche
$46 billion
March 2009